Novartis Pharmaceuticals – Myelofibrosis

Access Program Information

<p>The primary objective of this study is collect additional safety of <strong>INC424</strong> <strong>(Ruxolitinib)</strong> in patients with <em>Primary Myelofibrosis</em>, <em>Post Polycythemia Myelofibrosis</em> or <em>Post-essential Thrombocythemia Myelofibrosis</em>, who have either received prior treatment with commercially available agents or who have never received treatment.</p>
<p>The expanded access program (NCT01493414) is no longer available. Please call the manufacturer for further information or see new expanded access program for <em>Polycythemia vera</em> (NCT02292446).</p>

Rare Disease: